TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03950973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareAvenue
Description: CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guest Assistance Program
Description: The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
Study: NCT04524611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Subcutaneous (SC) injection
Study: NCT00893464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Study: NCT01785355

Intervention type: OTHER
Intervention: Dental treatment
Description: 1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions.
Study: NCT02055404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A spherical contact lens with molded marks
Description: Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lens
Description: Hydrogel toric contact lens for daily wear, daily disposable use
Study: NCT02113670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUI 1
Description: instillation of 50ml of air into the urinary bladder before the urodynamic test
Study: NCT00236080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROVIGIL 200 mg
Description: PROVIGIL 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Description: Armodafinil 250 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Description: Armodafinil 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Description: Armodafinil 150 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT04297462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 3 days
Description: Non-inferiority study of 3 versus 7-days duration of PEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 7 days
Description: Active comparator
Study: NCT01214044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/escitalopram
Description: Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
Study: NCT02400255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Study: NCT00599417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial Lysates
Description: Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo controlled
Study: NCT02185937

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cola
Description: imatinib intake with coca-cola
Study: NCT00936988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
Study: NCT04272567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
Study: NCT04255667

Intervention type: PROCEDURE
Intervention: Eyelid margin crush
Description: after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done

Intervention type: PROCEDURE
Intervention: Eyelid margin crush
Description: after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
Study: NCT04040361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
Study: NCT02714478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: equistasi
Description: 3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
Study: NCT00464204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 % Hydroxyethylstarch 130/0.4 = Voluven®
Description: Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 % NaCl
Description: NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
Study: NCT01653119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
Study: NCT01988389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole apples (WA)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: apple juice (AJ)
Study: NCT04447885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
Study: NCT04552678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Literacy Only
Description: Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
Study: NCT04182464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Food additive used to replace sugar providing a sweet taste without calories
Study: NCT02920788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Attentional Self-Regulation (GOALS)
Description: GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
Study: NCT02069665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuxiong San
Description: external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Study: NCT02920788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education (BHE)
Description: BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging of the Brain
Study: NCT04182464

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch without significant physiological effects
Study: NCT04090775

Intervention type: DRUG
Group type: OTHER
Intervention: Opdivo Injectable Product
Description: Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected.

Intervention type: DRUG
Group type: OTHER
Intervention: Yervoy Injectable Product
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected.
Study: NCT02920788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging of the Brain
Study: NCT04090775

Intervention type: DRUG
Group type: OTHER
Intervention: Cytoxan
Description: Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryosurgical freezing (cryosurgery)
Description: Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
Study: NCT00441792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate at induction dose based on weight
Study: NCT03373331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing Training
Description: Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Exercises
Description: Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
Study: NCT00441792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam at induction dose based on weight
Study: NCT02733874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Clobetasol Propionate Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Betamethasone Ointment
Study: NCT03715426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MKit
Description: MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
Study: NCT03437239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTS II Portable Tourniquet System
Description: This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
Study: NCT02069665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin Injection
Description: ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaoer Qingfei Heji (mixture)
Description: children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
Study: NCT03664375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Task Specific Training
Description: Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Specific Training
Description: Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
Study: NCT01187992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg/day
Study: NCT01302873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BGG492A
Study: NCT02100904

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation of fibroids

Intervention type: PROCEDURE
Intervention: Myomectomy of fibroids
Study: NCT00454493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor (omega-3-acid ethyl esters)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omacor (omega-3-acid ethyl esters)
Study: NCT00047346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00878839

Intervention type: DEVICE
Group type: OTHER
Intervention: Toric
Description: AcrySof Toric IOL
Study: NCT02069665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhi Ke San
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hua Tan San
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin Syrup
Description: children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
Study: NCT03096587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP Endo Finisher
Description: a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic activated irrigation
Description: by Satelec,Acteon, France
Study: NCT04642742

Intervention type: DIETARY_SUPPLEMENT
Intervention: Chewable plant sterol
Description: Chewable plant sterol (gummy)
Study: NCT03543410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 200 mg
Description: SEP-4199 200 mg/day (supplied in two 100mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 400 mg
Description: SEP-4199 400 mg/day (supplied in two 200mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (supplied in two tablets/day)
Study: NCT02902120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Grazoprevir and Elbasvir
Description: Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
Study: NCT02952976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abthera
Description: ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barker
Description: In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
Study: NCT04697329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preincisional infiltration with levobupivacaine
Description: Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
Study: NCT00666926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg twice daily \[BID\] with food, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg BID with food, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg BID with food, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg BID with food, tablet
Study: NCT00983190

Intervention type: DEVICE
Group type: OTHER
Intervention: Left Ventricular Assist Device (HeartMate II)
Description: The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt